Jodie M Fleming
Biography
Dr. Fleming’s research focuses on identifying the molecular mechanisms by which highly metastatic breast carcinomas tend to predominate in Black women and identifying candidate targets for therapeutics. Dr. Fleming has an extensive background in molecular and cellular physiology and in tissue/paracrine cell interactions, with specific expertise in breast cancer.
She often uses her unique background as an animal scientist to translate animal models to human disease, as well as to expand and develop novel “out of the box” ideas in the field of human cancer research. To this end, she was awarded the NCI Directors Intramural Innovation Award from Dr. Harold Varmus during her tenure at the National Cancer Institute (NCI) at the National Institutes of Health (NIH).
Having made significant success at the NCI, she accepted a position at NCCU and had the remarkable opportunity to join both the Lineberger Comprehensive Cancer Center (LCCC) at UNC-Chapel Hill as well as the Center for Human Health and the Environment (CHHE) at North Carolina State University. Her collaborative research programs with these institutes focus on detailed molecular studies to delineate the biological and cell physiological mechanisms that lead to contemporary problems associated with breast cancer outcomes. Specifically, she integrates aspects of cell behavior with the soluble and structural components (extracellular matrix) of the tissue microenvironment and clinical factors such as race, metabolic status, and diet to propel their foundation studies into clinically relevant, novel data.
As PI or co-investigator on several NIH-, Komen-, and University-funded grants, Dr. Fleming has laid the groundwork for executing successful research programs. She has developed unique model systems and a wealth of tools, techniques and resources to study altered gene expression, protein function, and tumor-matrix interactions in vitro and in vivo.
Intimately connected with Dr. Fleming’s drive to advance our scientific understanding of breast cancer is her desire to mentor and train the next generation of biomedical scientists who will continue to advance the biomedical research field. Her position with NCCU, LCCC and the CHHE provides her with the opportunity to recruit and mentor women in science, engage and excite minority and underserved students in cancer research.
Learn more about Dr. Fleming's work via the following links:
Education
|
PhD |
Rutgers University |
2006 |
|
BS |
University of Delaware |
2000 |
Courses
Publications
1. Martin ME, Reaves DK, Jeffcoat B, Enders JR, Costantini LM, Yeyeodu ST, Botta D, Kavanagh TJ, Fleming JM. Silver nanoparticles alter epithelial basement membrane integrity, cell adhesion molecule expression, and TGF-β1 secretion. Nanomedicine. 2019 Oct;21:102070. doi: 10.1016/j.nano.2019.102070. Epub 2019 Jul 24. PubMed PMID: 31351238; PubMed Central PMCID: PMC6814557.
2. Yeyeodu ST, Martin ME, Reaves DK, Enders JR, Costantini LM, Fleming JM. Experimental data demonstrating the effects of silver nanoparticles on basement membrane gene and protein expression in cultured colon, mammary and bronchial epithelia. Data Brief. 2019 Oct;26:104464. doi: 10.1016/j.dib.2019.104464. eCollection 2019 Oct. PubMed PMID: 31667234; PubMed Central PMCID: PMC6811978.
3. Barrow MA, Martin ME, Coffey A, Andrews PL, Jones GS, Reaves DK, Parker JS, Troester MA, Fleming JM. A functional role for the cancer disparity-linked genes, CRYβB2 and CRYβB2P1, in the promotion of breast cancer. Breast Cancer Res. 2019 Sep 11;21(1):105. doi: 10.1186/s13058-019-1191-3. PubMed PMID: 31511085; PubMed Central PMCID: PMC6739962.
4. Parada H Jr, Sun X, Fleming JM, Williams-DeVane CR, Kirk EL, Olsson LT, Perou CM, Olshan AF, Troester MA. Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study. Breast Cancer Res. 2017 Dec 11;19(1):131. doi: 10.1186/s13058-017-0914-6. PubMed PMID: 29228969; PubMed Central PMCID: PMC5725885.
5. Reaves DK, Hoadley KA, Fagan-Solis KD, Jima DD, Bereman M, Thorpe L, Hicks J, McDonald D, Troester MA, Perou CM, Fleming JM. Nuclear Localized LSR: A Novel Regulator of Breast Cancer Behavior and Tumorigenesis. Mol Cancer Res. 2017 Feb;15(2):165-178. doi: 10.1158/1541-7786.MCR-16-0085-T. Epub 2016 Nov 17. PubMed PMID: 27856957; PubMed Central PMCID: PMC5290211.
6. D'Arcy M, Fleming J, Robinson WR, Kirk EL, Perou CM, Troester MA. Race-associated biological differences among Luminal A breast tumors. Breast Cancer Res Treat. 2015 Jul;152(2):437-48. doi: 10.1007/s10549-015-3474-4. Epub 2015 Jun 25. PubMed PMID: 26109344; PubMed Central PMCID: PMC4527078.
7. Reaves DK, Ginsburg E, Bang JJ, Fleming JM. Persistent organic pollutants and obesity: are they potential mechanisms for breast cancer promotion?. Endocr Relat Cancer. 2015 Apr;22(2):R69-86. doi: 10.1530/ERC-14-0411. Epub 2015 Jan 26. Review. PubMed PMID: 25624167; PubMed Central PMCID: PMC4352112.
8. Stiles BG, Pradhan K, Fleming JM, Samy RP, Barth H, Popoff MR. Clostridium and bacillus binary enterotoxins: bad for the bowels, and eukaryotic being. Toxins (Basel). 2014 Sep 5;6(9):2626-56. doi: 10.3390/toxins6092626. Review. PubMed PMID: 25198129; PubMed Central PMCID: PMC4179152.
9. Fagan-Solis KD, Reaves DK, Rangel MC, Popoff MR, Stiles BG, Fleming JM. Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer. Mol Cancer. 2014 Jul 2;13:163. doi: 10.1186/1476-4598-13-163. PubMed PMID: 24990559; PubMed Central PMCID: PMC4086999.
10. Reaves DK, Fagan-Solis KD, Dunphy K, Oliver SD, Scott DW, Fleming JM. The role of lipolysis stimulated lipoprotein receptor in breast cancer and directing breast cancer cell behavior. PLoS One. 2014;9(3):e91747. doi: 10.1371/journal.pone.0091747. eCollection 2014. PubMed PMID: 24637461; PubMed Central PMCID: PMC3956714.
11. Fleming JM, Ginsburg E, McAndrew CW, Heger CD, Cheston L, Rodriguez-Canales J, Vonderhaar BK, Goldsmith P. Characterization of Δ7/11, a functional prolactin-binding protein. J Mol Endocrinol. 2013 Feb;50(1):79-90. doi: 10.1530/JME-12-0201. Print 2013 Feb. PubMed PMID: 23048206; PubMed Central PMCID: PMC3561765.
12. Casbas-Hernandez P, D'Arcy M, Roman-Perez E, Brauer HA, McNaughton K, Miller SM, Chhetri RK, Oldenburg AL, Fleming JM, Amos KD, Makowski L, Troester MA. Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Res. 2013;15(5):R82. doi: 10.1186/bcr3476. PubMed PMID: 24025166; PubMed Central PMCID: PMC3978616.
13. Fleming JM, Miller TC, Kidacki M, Ginsburg E, Stuelten CH, Stewart DA, Troester MA, Vonderhaar BK. Paracrine interactions between primary human macrophages and human fibroblasts enhance murine mammary gland humanization in vivo. Breast Cancer Res. 2012 Jun 25;14(3):R97. doi: 10.1186/bcr3215. PubMed PMID: 22731827; PubMed Central PMCID: PMC3446360.
14. Fleming JM, Ginsburg E, Oliver SD, Goldsmith P, Vonderhaar BK. Hornerin, an S100 family protein, is functional in breast cells and aberrantly expressed in breast cancer. BMC Cancer. 2012 Jun 22;12:266. doi: 10.1186/1471-2407-12-266. PubMed PMID: 22727333; PubMed Central PMCID: PMC3464886.
15. Fleming JM, Ginsburg E, Goldhar AS, Plant J, Vonderhaar BK. Progesterone receptor activates Msx2 expression by downregulating TNAP/Akp2 and activating the Bmp pathway in EpH4 mouse mammary epithelial cells. PLoS One. 2012;7(3):e34058. doi: 10.1371/journal.pone.0034058. Epub 2012 Mar 22. PubMed PMID: 22457812; PubMed Central PMCID: PMC3310875.
16. Casbas-Hernandez P, Fleming JM, Troester MA. Gene expression analysis of in vitro cocultures to study interactions between breast epithelium and stroma. J Biomed Biotechnol. 2011;2011:520987. doi: 10.1155/2011/520987. Epub 2011 Dec 13. Review. PubMed PMID: 22203785; PubMed Central PMCID: PMC3238808.
17. Fleming JM, Miller TC, Meyer MJ, Ginsburg E, Vonderhaar BK. Local regulation of human breast xenograft models. J Cell Physiol. 2010 Sep;224(3):795-806. doi: 10.1002/jcp.22190. PubMed PMID: 20578247; PubMed Central PMCID: PMC2897719.
18. Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E, Vonderhaar BK. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 2010 Jun 1;70(11):4624-33. doi: 10.1158/0008-5472.CAN-09-3619. Epub 2010 May 18. PubMed PMID: 20484027; PubMed Central PMCID: PMC4129519.
19. Fleming JM, Miller TC, Quinones M, Xiao Z, Xu X, Meyer MJ, Ginsburg E, Veenstra TD, Vonderhaar BK. The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo. BMC Med. 2010 May 21;8:27. doi: 10.1186/1741-7015-8-27. PubMed PMID: 20492690; PubMed Central PMCID: PMC2894739.
20. Faupel-Badger JM, Ginsburg E, Fleming JM, Susser L, Doucet T, Vonderhaar BK. 16 kDa prolactin reduces angiogenesis, but not growth of human breast cancer tumors in vivo. Horm Cancer. 2010 Apr;1(2):71-9. doi: 10.1007/s12672-010-0012-z. PubMed PMID: 21113329; PubMed Central PMCID: PMC2990984.
21. Meyer MJ, Fleming JM, Ali MA, Pesesky MW, Ginsburg E, Vonderhaar BK. Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res. 2009;11(6):R82. doi: 10.1186/bcr2449. Epub 2009 Nov 11. PubMed PMID: 19906290; PubMed Central PMCID: PMC2815544.
22. Fleming JM, Long EL, Ginsburg E, Gerscovich D, Meltzer PS, Vonderhaar BK. Interlobular and intralobular mammary stroma: genotype may not reflect phenotype. BMC Cell Biol. 2008 Aug 18;9:46. doi: 10.1186/1471-2121-9-46. PubMed PMID: 18710550; PubMed Central PMCID: PMC2529294.
23. Fleming JM, Brandimarto JA, Cohick WS. The mitogen-activated protein kinase pathway tonically inhibits both basal and IGF-I-stimulated IGF-binding protein-5 production in mammary epithelial cells. J Endocrinol. 2007 Aug;194(2):349-59. doi: 10.1677/JOE-06-0121. PubMed PMID: 17641284.
24. Fleming JM, Desury G, Polanco TA, Cohick WS. Insulin growth factor-I and epidermal growth factor receptors recruit distinct upstream signaling molecules to enhance AKT activation in mammary epithelial cells. Endocrinology. 2006 Dec;147(12):6027-35. doi: 10.1210/en.2006-0349. Epub 2006 Sep 21. PubMed PMID: 16990343.
25. Fleming JM, Leibowitz BJ, Kerr DE, Cohick WS. IGF-I differentially regulates IGF-binding protein expression in primary mammary fibroblasts and epithelial cells. J Endocrinol. 2005 Jul;186(1):165-78. doi: 10.1677/joe.1.06164. PubMed PMID: 16002546.
26. Sivaprasad U, Fleming J, Verma PS, Hogan KA, Desury G, Cohick WS. Stimulation of insulin-like growth factor (IGF) binding protein-3 synthesis by IGF-I and transforming growth factor-alpha is mediated by both phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways in mammary epithelial cells. Endocrinology. 2004 Sep;145(9):4213-21. doi: 10.1210/en.2003-1377. Epub 2004 Jun 10. PubMed PMID: 15192040.